Back to User profile » Dr Chris Coppin
Paper published by Dr Chris Coppin:
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
Chris Coppin
Biologics: Targets and Therapy 2010, 4:91-101
Published Date: 30 April 2010